Auto-immutable.

Various immunotherapy options are fast becoming preferred for most patients with non-small cell lung cancer (NSCLC). Except for those with autoimmune disorders (AID), banned from trials designed to succeed. A multi-institutional retrospective look at 56 patients with a wide array of AID treated with PD-1 axis inhibitors for NSCLC reports 13 (23%) experienced AID flare, 8 (14%) required steroids, and 8 had to discontinue therapy. Not bad considering these meds aren’t a walk in the park even without preexisting autoimmunity. | Leonardi, J Clin Oncol 2018